Phenotypes associated with this allele
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nle1tm1Cba mutation
(0 available);
any
Nle1 mutation
(27 available)
|
|
|
mortality/aging
|
• died around E5.5 - E6.5
|
embryo
|
• the inner cell mass fails to expand and displays a significant increase in the number of apoptotic cells, but no change in cell proliferation
• however, no change in the number of trophectodermal cells is detected
|
|
• most (17 of 21) blastocysts fail to hatch out of the zona pellucida after 3 days in culture
|
cellular
|
• the inner cell mass fails to expand and displays a significant increase in the number of apoptotic cells, but no change in cell proliferation
• however, no change in the number of trophectodermal cells is detected
|
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm2(cre/ERT2)Brn mutation
(1 available);
any
Gt(ROSA)26Sor mutation
(944 available)
Nle1tm1.1Cota mutation
(0 available);
any
Nle1 mutation
(27 available)
Nle1tm1Cba mutation
(0 available);
any
Nle1 mutation
(27 available)
|
|
|
Severe hypocellularity in Nle1tm1Cba/Nle1tm1.1Cota Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+ bone marrow, with capillaries saturated with erythrocytes
mortality/aging
|
• mice die 10 to 13 days after tamoxifen treatment
|
immune system
|
• in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
• defects in secondary lymphoid organs in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
digestive/alimentary system
|
• 7 to 9 days after tamoxifen treatment
|
cellular
|
• tamoxifen-treated mice exhibit impaired biogenesis of large ribosomal subunit in hematopoietic stem cell and multipotent progenitor compared with control mice
|
hematopoietic system
N |
• hematopoietic stem cell mobilization occurs normally in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
• tamoxifen-treated mice exhibit cell autonomous defects in hematopoiesis
|
|
• in tamoxifen-treated mice
• tamoxifen-treated mice exhibit impaired biogenesis of large ribosomal subunit in hematopoietic stem cell and multipotent progenitor compared with control mice
|
|
• in tamoxifen-treated mice
|
|
• severe in tamoxifen-treated mice
|
|
• decreased in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
• in tamoxifen-treated mice
|
|
• reduced hematopoietic stem cell and multipotent progenitor quiescence in tamoxifen-treated mice
|
endocrine/exocrine glands
|
• in tamoxifen-treated mice
|
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm2(cre/ERT2)Brn mutation
(1 available);
any
Gt(ROSA)26Sor mutation
(944 available)
Nle1tm1.1Cota mutation
(0 available);
any
Nle1 mutation
(27 available)
Nle1tm1Cba mutation
(0 available);
any
Nle1 mutation
(27 available)
Trp53tm1Tyj mutation
(12 available);
any
Trp53 mutation
(232 available)
|
|
|
hematopoietic system
N |
• tamoxifen-treated mice exhibit rescued total bone marrow and LSK cells
|
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation
(11 available);
any
Cd19 mutation
(56 available)
Nle1tm1.1Cota mutation
(0 available);
any
Nle1 mutation
(27 available)
Nle1tm1Cba mutation
(0 available);
any
Nle1 mutation
(27 available)
|
|
|
hematopoietic system
N |
• mice exhibit normal numbers of bone marrow pre-B cells, immature B cells and splenic mature B cells
• mice exhibit normal survival, proliferation and maturation of restricted progenitors
|
immune system
N |
• mice exhibit normal numbers of bone marrow pre-B cells, immature B cells and splenic mature B cells
• mice exhibit normal survival, proliferation and maturation of restricted progenitors
|